"99mTc-maraciclatide" Granted FDA Fast Track Designation for the Diagnosis of Superficial Peritoneal Endometriosis

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 07/02/2024.
  • Additional Information
    • Alternate Title:
      Serac-Healthcare
    • Abstract:
      LONDON, July 2, 2024 /PRNewswire/ -- Serac Healthcare Limited, a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation to 99mTc-maraciclatide as a diagnostic SPECT-CT agent for the visualisation and diagnosis of superficial peritoneal endometriosis in women of 16 years and older. [ABSTRACT FROM PUBLISHER]